Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Duopharma Biotech Bhd's intangible assets for the quarter that ended in Mar. 2026 was RM35.9 Mil.
Duopharma Biotech Bhd (XKLS:7148) Intangible Assets Explanation
If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.
The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.
Some intangibles are amortized. Amortization is the depreciation of intangible assets.
Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.
Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.
If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.
Intangibles acquired are on balance sheet at fair value.
Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.
One of the reasons competitive advantage power can remain hidden for so long.
Be Aware
Companies may change the way intangible assets are amortized, and this will affect their reported earnings.
Duopharma Biotech Bhd Intangible Assets Related Terms
Duopharma Biotech Bhd Intangible Assets Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Intangible Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd Intangible Assets Calculation
Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.
Duopharma Biotech Bhd (XKLS:7148) has a Intangible Assets of RM35.9 Mil as of Mar. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's Intangible Assets too high?
Duopharma Biotech Bhd's current Intangible Assets is RM35.9 Mil. Overall, Duopharma Biotech Bhd has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Intangible Assets compare to ZTS and UTHR?
Duopharma Biotech Bhd's Intangible Assets of RM35.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Drug Manufacturers company?
A good Intangible Assets depends on the Drug Manufacturers industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current Intangible Assets is RM35.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.55, compared to a current price of RM1.25 — trading 19.4% below its estimated fair value. The current Intangible Assets is RM35.9 Mil. Duopharma Biotech Bhd's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Intangible Assets is RM35.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.25 is trading 19.4% below its estimated GF Value™ of RM1.55.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Intangible Assets: RM35.9 Mil
GF Value™: RM1.55 vs. price of RM1.25 (19.4% below fair value)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
79GF Score
Get the complete analysis for XKLS:7148
Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
